DongBang Medical Co Ltd

DongBang Medical has a strong liquidity position, as evidenced by its operating cash flow of KRW 4,006,579,940 and free cash flow of KRW 3,023,619,220. The company's capital structure is supported by a relatively low number of shares outstanding, with both basic and diluted shares at 20,810,260. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in the source documents.

In terms of profitability, DongBang Medical reported a net income of KRW 2,364,886,350 and an operating income of KRW 3,417,402,540. The company's gross profit of KRW 7,781,710,670 indicates a healthy margin, which is a key performance indicator in the medical equipment and supplies industry. These figures suggest that the company is performing well relative to industry standards, although direct comparisons to cohort medians are not available in the current dataset.

DongBang Medical's revenue is concentrated in a single business segment, as disclosed in its financial reports. The company's geographic exposure is primarily within South Korea, with no significant international operations reported in the available data. This concentration may pose a risk if the domestic market experiences economic downturns or regulatory changes.

The company's growth trajectory is positive, with a revenue of KRW 24,203,638,220 reported in the latest financial period. While specific growth rates are not provided, the consistent operating and free cash flows suggest a stable and potentially growing business. Analysts have provided a mean price target of KRW 19,000, indicating a strong buy recommendation.

Dilution risk is currently low for DongBang Medical, as there is no evidence of significant share issuance or dilution potential in the near term. The company's capital expenditure of KRW -733,773,790 suggests a focus on maintaining and optimizing existing operations rather than aggressive expansion. This conservative approach to capital spending may help preserve liquidity and reduce the need for external financing.

Recent events and filings do not indicate any major operational or financial disruptions for DongBang Medical. The company's financial reports and analyst estimates suggest a stable and well-managed business. However, the lack of detailed segment and geographic breakdowns in the available data limits the ability to fully assess the company's exposure to different markets and product lines.

Revenue KRW 113.54B, +8,0% YoY; Operating income +21,9% YoY.

• ▍Revenue KRW 113.54B, +8,0% YoY
• ▍Operating income +21,9% YoY
• ▍Net income +301,6% YoY
• ▍Free cash flow +192,3% YoY
• ▍Net margin 10.3%